More importantly, randomized controlled trials should systematically assess the synergistic effects and safety of combined PDE5 inhibitors and anti-inflammatory therapies, while also paying attention to the potential impacts of various IBD drugs themselves on the gonadal axis and mood, to comprehensively weigh benefits against risks. Here, PDE5A is linked to irritable bowel syndrome.